Enzymatica AB: Enzymatica signs agreement with Qualia Pharma for Greece and Cyprus
May 22 2018 - 2:30AM
Press release
Lund May 22, 2018
Enzymatica signs agreement with
Qualia Pharma for Greece and Cyprus
Enzymatica has entered into a
distribution agreement with Qualia Pharma for marketing and sales
of ColdZyme® Mouth Spray on the Greek and Cypriot market. The
background to the agreement is that Qualia Pharma acquired Life NLB
on March 1, 2018. The distribution agreement that Enzymatica
previously had with Life NLB is now being transferred to Qualia
Pharma.
"We
see a clear advantage to signing an agreement with Qualia Pharma,
which is a larger market participant and can conduct a stronger
marketing campaign for ColdZyme in Greece and on Cyprus," says
Fredrik Lindberg, CEO of Enzymatica.
"We
see excellent potential for ColdZyme in our market, given the
successful launch in other European markets. We consider being able
to sell a product that attacks the cause of colds - viruses - to be
a major advantage compared with most cold products, which are aimed
at alleviating symptoms," says Fotis Sakellaridis, CEO of Qualia
Pharma.
The Greek and Cypriot cold products market, which is estimated to
be worth SEK 670 million, is a stable market. ColdZyme began to be
sold to pharmacies in both markets in 2017. In 2018 a launch was
initiated targeting consumers, pharmacists and healthcare
personnel.
Qualia Pharma is a Greek pharmaceutical company
active in pharmaceuticals, nutritional supplements and medical
devices. The company was founded in 2009 and conducts research in
fields such as osteoarthritis, diseases of the central nervous
system (CNS) such as Alzheimer's and Parkinson's, and biological
products for development of drug molecules. Qualia Pharma conducts
research in collaboration with universities and research
institutes. The company has 43 employees and sales of SEK 50
million.
For
more information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email:
fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and
sells medical devices for infection-related diseases. The products
are based on a barrier technology that includes marine enzymes. The
company's first product is ColdZyme® Mouth Spray, which can prevent
colds and reduce the duration of disease. The product has been
launched in about ten markets. The strategy is to continue to grow
by strengthening the Company's position in existing markets and
expanding into new geographic markets through established partners.
The company has its headquarters in Lund and is listed on Nasdaq
First North. For more information,
visit: www.enzymatica.com.
Enzymatica's certified adviser is Erik Penser
Bank.För mer information, kontakta:
Fredrik Lindberg, VD Enzymatica AB
Tel: 0708-86 53 70 | E-post:
fredrik.lindberg@enzymatica.com
Om Enzymatica AB
Enzymatica AB är ett life science-bolag som
utvecklar och säljer medicintekniska produkter mot
infektionsrelaterade sjukdomar. Produkterna är baserade på en
barriärteknologi, som inkluderar marina enzymer. Bolagets första
produkt är ColdZyme® Munspray som kan förhindra förkylning, och kan
förkorta sjukdomsperioden. Produkten har lanserats på ett tiotal
marknader. Strategin är att fortsätta växa genom att stärka
positionen på befintliga marknader och expandera till fler
geografiska marknader via etablerade partners. Bolaget har
huvudkontor i Lund och är listat på Nasdaq First North. För mer
information, besök: www.enzymatica.se.
Enzymaticas Certified Adviser är Erik Penser
Bank.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From May 2024 to Jun 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2023 to Jun 2024